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ABSTRACT
Background and the purpose of the study: Itraconazole is a poorly water soluble drug which 
results in its insufficient bioavailability. The purpose of the present study was to formulate 
Itraconazole in a nanosuspension to increase the aqueous solubility and to improve its formulation 
related parameters, dissolution and hence oral bioavailability.
Methods: Itraconazole nanosuspension was prepared by pearl milling technique using zirconium 
oxide beads as a milling media, Poloxamer 407 as a stabilizer and glycerol as a wetting agent. 
Effects of various process parameters like, stirring time and the ratio of the beads were optimized 
by keeping drug:surfactant:milling media (1:3.0:50) as a constant initially and then optimized 
process parameters were used to optimize formulation parameters by 32 factorial designs. 
The optimized nanosuspension was lyophilized using mannitol (1:1 ratio) as a cryoprotectant. 
Nanosuspension was characterized by particle size and size distribution, drug content, scanning 
electron microscopy, differential scanning colorimetry and X-ray diffraction techniques.
Results:Optimized nanosuspension showed spherical shape with surface oriented surfactant 
molecules and a mean particle diameter of 294 nm. There was no significant change in crystalline 
nature after formulation and it was found to be chemically stable with high drug content. 
Conclusion: The in vitro dissolution profile of the optimized formulation compared to the pure 
drug and marketed formulation (Canditral Capsule) by using 0.1N Hydrochloric acid as release 
medium showed higher drug release.
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INTRODUCTION
Itraconazole is an orally active triazole antimycotic 
agent, which is active against a broad spectrum of 
fungal  species  including  Cryptococcus,  Candida, 
Aspergillus, Blastomyces and Histoplasma capsulatum 
var. capsulatum (1, 2). It is a weak basic drug which 
is soluble in lipids (n- Octanol/Water partition, 5.66 
at pH of 8.1) and a pKa of 3.7 (3). Itraconazole is 
ionized only at a low pH, such as gastric juice and as 
a result on oral administration, the gastric acidity is 
required for adequate dissolution. The bioavailability 
of  itraconalzole  is  known  to  be  increased  after  a 
meal in comparison to the fasting state. Since the 
bioavailability  of  poorly  water-soluble  drugs  can 
be influenced by interactions with food or by the 
physicochemical conditions of the gastrointestinal 
(GI)  tract,  oral  preparation  of  itraconazole  is 
commonly prescribed to be administered according 
to a fixed dosing schedule, especially, to be taken 
immediately after meals. The oral bioavailability of 
itraconazole is maximal when it is taken with a full 
meal.
Poor water solubility of drug molecules, insufficient 
bioavailability, fluctuating plasma levels and high food 
dependency  are  the  most  important  and  common 
problems with this drug. Major efforts have been made 
for  the  development  of  customized  drug  carriers 
to overcome the disappointing in vivo fates of the 
drug (4, 5). Hence, there is a growing need for a 
unique  strategy  that  can  tackle  the  formulation 
related  problems  associated  with  the  delivery  of 
hydrophobic drugs in order to improve their clinical 
efficacy and optimize their therapy with respect to 
pharmacoeconomics. 
The dissolution rate of poorly water soluble-drugs 
often becomes a rate-limiting step in their absorption 
from GI tract (6, 7). Various solubilization methods 
have been used to increase the drug solubility and 
dissolution properties, including the use of surfactant, 
water-soluble  carriers,  polymeric  conjugates,  and 
solid dispersion.    
Preparation of drugs in form of nanosuspensions has 
shown to be a more cost-effective and technically 
simpler alternative, particularly for poorly soluble 
84Poloxamer 407 was purchased from BASF (Germany). 
Glycerol and Mannitol were purchased from S.d fine 
chemicals (India).
Preparation of Nanosuspension
Itraconazole powder (1%w/v) was dispersed in an 
aqueous solution containing glycerol (2.2%w/v) and 
different ratio of Poloxamer 407 in 20 ml vial. The 
resulting  coarse  pre-dispersion  was  comminuted 
using zirconium oxide beads (milling media) on a 
magnetic stirrer. Zirconium oxide beads were used 
in the preparation of nanosuspension due to their low 
cost and easy availability for lab scale production 
of  nanosuspension  in  comparison  to  silver beads. 
Various parameters like the effect of stirring time 
and ratio of different size of zirconium oxide beads 
were  optimized  by  keeping  the  drug:  surfactant: 
milling media volume (1:3:50) as constant initially, 
then the optimized conditions of stirring time and 
ratio of different size of zirconium oxide beads were 
used throughout the study to optimize concentration 
of  Poloxamer  407  and  volume  of  milling  media 
using  32  factorial  designs  to  achieve  minimum 
particle size (Table 1). The stirring was continued for 
24 hrs at 750 rpm for the preparation of optimized 
nanosuspension formulation. The optimized formulation 
was lyophilized using mannitol as a cryoprotectant 
(1:1  ratio).  Lyophilized  nanosuspension  was  used 
for further study. 
drugs, and yield a physically more stable product 
than  liposome  dispersions  (8-10).  With  this 
technique, the drug, dispersed in water, is grounded 
by shear forces to particles with a mean diameter in 
the nanometer range (100-1000nm). The fineness of 
the dispersed particles causes them to dissolve more 
quickly owing to their higher dissolution pressure and 
leads to an increased saturation solubility. This may 
enhance the bioavailability of drugs compared with 
other microparticular systems. If in vivo dissolution 
velocity of the drug particles is low enough, the drug 
nanosuspensions  will  have  the  passive  targeting 
advantages of colloidal drug carriers (11).
The  aim  of  this  study  was,  to  employ  the 
nanosuspension technique to produce itraconazole 
nanoparticles  for  oral  administration,  thereby 
avoiding the use of harmful additives and enabling to 
enhance the saturation solubility, dissolution and 
oral absorption of itraconazole. The optimized 
nanosuspension formulation was evaluated for in 
vitro dissolution profile in comparison to the pure 
drug and marketed formulation (Canditral Capsule).
MATERIAL AND METHODS
Materials 
Itraconazole was a gift from Intas pharmaceutical 
limited  (India).  Zirconium  oxide  beads  were  gifted 
from  Sun  Pharmaceutical  Industries  Ltd.  (India).   
Batch No. X1 X2
ITZ1 2.5 40
ITZ2 2.5 50
ITZ3 2.5 60
ITZ4 3.0 40
ITZ5 3.0 50
ITZ6 3.0 60
ITZ7 3.5 40
ITZ8 3.5 50
ITZ9 3.5 60
Table 1. 32 factorial design lay out for preparation of Itraconazole 
nanosuspension.
X1, Concentration of stabilizer (Poloxamer 407) (%w/v).
X2, % v/v of Milling Media (Zirconium oxide beads).
Batch. No. Time (hrs) Mean particle size [D(4,3)]
IT1 Initial (5min.) 176.49µm
IT2 2 3.060µm
IT3 4 2.328µm
IT4 6 1.824µm
IT5 8 1.368µm
IT6 10 1.309µm
IT7 12 1.225µm
IT8 24 0.317µm
IT9 26 0.552µm
IT10 28 0.678µm
Table 2. Effect of stirring time on particle size of itraconazole 
nanosuspension.
Table 3. Effect of Ratio of beads on particle size of itraconazole nanosuspension 
Batch. No. Ratio of beads (Zirconium Oxide)
Mean particle size [D(4,3)] Small Size  (0.4mm to 0.7mm ) Big Size (1.2mm to 1.7mm)
TSB1 0 100 1.142µm 
TSB2 25 75 0.674µm 
TSB3 50 50 0.315µm
TSB4 75 25 0.865µm
TSB5 100 0 1.315µm
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No.
Conc. 
of drug
(% w/v)
Conc. stabilizer
(Poloxamer 407)
(% w/v)
% v/v of Milling 
Media (Zirconium 
oxide beads)
Particlesize before 
Lyophilization 
[d (4, 3)]
Polydispersity 
index
Particle size after 
Lyophilization 
[d (4, 3)]
Polydis 
persity index
ITZ1 1 2.5 40 0.747µm 0.512 0.754µm 0.523
ITZ2 1 2.5 50 0.516µm 0.419 0.523µm 0.428
ITZ3 1 2.5 60 0.696µm 0.489 0.707µm 0.508
ITZ4 1 3.0 40 0.379µm 0.376 0.392µm 0.389
ITZ5 1 3.0 50 0.283µm 0.307 0.294µm 0.318
ITZ6 1 3.0 60 0.324µm 0.453 0.358µm 0.461
ITZ7 1 3.5 40 0.501µm 0.392 0.515µm 0.402
ITZ8 1 3.5 50 0.438µm 0.543 0.448µm 0.554
ITZ9 1 3.5 60 0.492µm 0.465 0.505µm 0.481
Table 4. Optimization of formulation parameters for the preparation of itraconazole nanosuspension.
Figure 1. Photomicrograph of scanning electron micrographs of 
pure itraconazole powder. 
Figure 2. Photomicrograph of scanning electron micrographs of   
itraconazole  nanosuspension formulation.
Particle size and Size distribution
The mean particle diameter and size distribution of 
the prepared nanosuspension was measured by laser 
diffraction  technique  using  Malvern  particle  size 
analyzer, SM 2000. Nanosuspension was added to 
the sample dispersion unit, and stirred at 2000 rpm 
with magnet in order to reduce the interparticulate 
aggregation, and laser obscuration range was maintained 
between 10-20 %. The average particle size was 
measured after performing the experiment in triplicates.
Scanning Electron Microscopy (SEM)
The lyophilized powder for nanosuspension formulation 
was kept in the sampling unit as a thin film and then 
photographs  were  taken  at  100X  and  200X 
magnification using Jeol Scanning Electron Microscope 
(Jeol, JSM-840 SEM Japan).
Differential Scanning Calorimetry (DSC) 
The DSC thermograms of bulk Itraconazole powder 
and  lyophilized  nanosuspension  formulation 
were taken on a Mettler Toledo Star SW 7.01 DSC 
differential scanning colorimeter between 30-300°C 
at a heating rate of 10°C/min with Nitrogen supply 
at 50.0 ml/min.
X-ray Diffraction pattern (XRD)
The  study  was  carried  out  at  Punjab  University, 
Chandigadh,  India.  The  XRD  thermograms 
of  Bulk  Itraconazole  powder  and  lyophilized 
nanosuspension  formulation  were  carried  on 
Philips PW 1710 X-ray generator (Philips, Amedo, 
the Netherlands).
In vitro dissolution profile 
In vitro dissolution study was performed using USP 
dissolution test apparatus-I (basket assembly). The 
dissolution  was  performed  using  500  ml  of  0.1N 
HCl  and  900  ml  phosphate  buffer  solution  (PBS) 
of  pH  6.8  as  dissolution  mediums  maintained  at 
37 ± 0.5°C and 100 rpm for pure drug, lyophilized 
itraconazole nanosuspension formulation and marketed 
formulation  (Canditral  capsule).  Samples  (5ml)  were 
withdrawn at regular intervals of 5 min for 60 min and 
replaced  with  fresh  dissolution  medium.  Samples 
were filtered through 0.2µ filter paper and assayed 
spectrophotometrically  on  SHIMADZU  UV-VISIBLE 
spectrophotometer UV-1601 at 255.0 nm wavelength. 
Dissolution  for  each  formulation  was  performed  in 
triplicates and mean of absorbance was  used to calculate 
cumulative  percent  of  drug  release (12).
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Assay was carried out by taking 10 mg of lyophilized 
powder  (weigh  equivalent  to  1.25  mg  of  drug), 
dissolved in 0.4 ml of tetrahydrofuran in 50 ml dry 
volumetric flask and then volume was made up using 
0.1 N HCl. Then 4 ml of the solution was taken to 10 
ml dry volumetric flask, and volume adjusted with 
0.1 N HCl. The absorbance at 255.0 nm wavelength 
was  taken  using  SHIMADZU  UV-VISIBLE 
spectrophotometer  UV-1601  and  the  drug  content 
was calculated accordingly (13).
RESULTS  AND  DISCUSSION 
Influence of various parameters on particle size and 
size distribution
As  shown  in  table  2,  effect  of  stirring  time  on 
particle size was optimized by keeping 50:50  ratio 
of  different diameter (0.4mm to 0.7mm and 1.2 mm 
to 1.7 mm) of zirconium oxide beads and keeping the 
drug: surfactant: milling media volume (1:3.0:50) 
constant.  Lowest  317  nm  mean  particle  size  was 
achieved  after  24  hrs  stirring  of  50:50  ratios  of 
zirconium oxide beads. Further stirring up to 28 hrs 
may lead to increased particle size due to increased 
surface free energy.
As shown in table 3, the effect of ratio of different 
size of zirconium oxide beads from 0.4 nm to 0.7 nm 
and 1.2 nm to 1.7 nm on particle size was optimized 
by  keeping  the  drug:  surfactant:  milling  media 
volume (1:3.0:50) constant and stirring for 24 hrs. 
Lowest particle size of 315 nm was observed at 50: 
50 resulting ratio of different size of zirconium oxide 
beads. When the ratios of different size of zirconium 
oxide beads were different than 50:50, resulting 
nanosuspensions had higher particle size (Table 3). 
One possible explanation is that at this ratio beads 
were closely packed and lead to reduced void space 
Figure 3. DSC thermograms of bulk Itraconazole powder
Figure 4.  DSC thermograms of Itraconazole nanosuspension formulation.
Nakarani et al / DARU 2010 18 (2) 84 -90 87Figure 5. XRD thermograms of bulk Itraconazole powder.
Figure 6. XRD thermograms of itraconazole nanosuspension formulation. 
Figure  8.  Dissolution  profile  for  nanosuspension  formulation 
(circle), pure drug (square), and marketed formulation (triangle) 
[mean ± SD (n=3)] in PBS pH 6.8.
Figure  7.  Dissolution  profile  for  nanosuspension  formulation 
(circle), pure drug (square), and marketed formulation (triangle) 
[mean ± SD (n=3)] in 0.1 N HCl.
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than this, the void spaces were found to be higher 
and attrition between drug particles and beads were 
at maximum. 
As  shown  in  table  4,  the  optimized  formulation 
showed  mean  particle  size  of  283  nm  with 
Polydispersity index of 0.307 (before lyophilization), 
with 3.0 % w/v of poloxamer 407 which was used 
as a stabilizer and 50 % v/v of milling media. After 
lyophilization a mean particle diameter was found 
to be 294 nm with Polydispersity index 0.318, so 
in  lyophilization  process  there  was  no  significant 
change in particle size and size distribution. 
No  significant  changes  in  particle  size  and 
polydispersity index demonstrate formation of stable 
non-flocculated  nanosuspension  of  itraconazole 
which was developed in this investigation (Table 4). 
Lowest mean particle size was achieved after 24 hrs 
stirring with milling media ratio of 0.4-0.7 mm and 
beads of diameter 1.2-1.7 mm at 50:50.  Increase in 
the media volume led to slight increase in the mean 
particle  diameter  but  did  not  lead  to  significant 
change by increasing the concentration of stabilizer. 
Further stirring resulted in increased mean particle 
diameter of Itraconazole nanosuspension which may 
be due to increased surface free energy.
Scanning electron microscopy (SEM)
SEM micrographs clearly showed great differences 
between pure itraconazole (Figure. 1) and optimized 
nanosuspension formulation (Figure. 2). The particles of 
itraconazole were found to be large and especially 
irregular (Figure. 1). However after formulation, particles 
disappeared and drug became small and uniform. 
The nanocrystals seem to be more rounded, perhaps 
because the particles were coated with a surfactant 
layer.  In  the  suspension  suolution,  the  surfactant 
which was used to stabilize the particles could be 
adsorbed to surface of the crystals by hydrophobic 
interaction.  Therefore,  after  lyophilization  of 
surfactants  an  amorphous  layer  formed  on  the 
surface of inner crystals. (14)
Differential Scanning Calorimetry (DSC) 
DSC  was  performed  to  investigate  the  effect  of 
surfactant  on  the  inner  structure  of  itraconazole 
nanosuspension.  figures  3  and  4  show  DSC 
thermograph of pure itraconazole powder and optimized 
nanosuspension  formulation  respectively.  Pure 
itraconazole  powder  showed  melting  exotherm  at 
168.38°C which corresponds to its melting point and its 
exotherm in formulation was observed at 165.58°C. 
From thermograms, it was concluded that the drug and 
the surfactant do not interact with each other (15).
 X-Ray Diffraction pattern (XRD)
X-Ray  diffraction  was  used  to  analyze  potential 
changes  in  the  inner  structure  of  itraconazole 
nanocrystal  during  the  formulation.  The  extent 
of  such  changes  depends  on  the  chemical  nature 
and physical hardness of the active ingredient (16).   
Figures 5 and 6 show XRD thermograph of pure 
itraconazole  powder,  poloxamer  407,  mannitol 
and  itraconazole  nanosuspension  formulation 
respectively. The obtained patterns reveal that the 
drug  crystallanity  of  nanosuspension  formulation 
was not affected significantly (15).
In vitro dissolution study
Dissolution studies were performed for pure drug, 
marketed  formulation  (Canditral  capsule)  and 
optimized  nanosuspension  formulation. The  amount 
of drug released from the optimized nanosuspension 
formulation was 90% within 10 min compared to 
amount of 10% and 17% for pure drug and marketed 
formulation  (Canditral  capsule)  respectively 
(Figure 7) in 0.1N HCl (pH 1.2) while in PBS (pH 
6.8) it was 92% as compared to 13% and 20% for 
pure  drug  and  marketed  formulation  (Canditral 
capsule)  respectively  (Figure  8).  The  increase  in 
accessible surface area to the dissolution medium 
and hydrophilic surfactant coating on the particle 
surfaces may be the reason for six fold increase in 
dissolution rate.
The drug content in the formulation was found to 
be 99.25% w/w of the amount of drug which was 
added theoretically. In the formulation no step was 
involved which could cause the drug loss hence a 
high amount of drug was obtained.
CONCLUSION
From the results of this study it may be concluded 
that  nanocrystalline  suspensions  of  poorly 
soluble  drugs  such  as  itraconazole  are  easy  to 
prepare  and  to  lyophilize  for  extended  storage 
and represent a promising new drug formulation 
for  oral  drug  delivery  for  treatment  of  fungal 
infection. Dissolution study in 0.1N HCl shows 
that nanosuspension formulation gives higher drug 
release  compared  to  the  pure  drug  and  marketed 
formulation.  Consequently  nanosuspensions 
represent a promising alternative to current delivery 
systems  aiming  to  improve  the  biopharmaceutic 
performance of drugs with low water solubility.
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